MGO One Seven LLC recently reduced its position in biotechnology firm Corcept Therapeutics by 8.2%, selling 551 shares and retaining 6,142 shares valued at $451,000. This adjustment, disclosed through an SEC filing, underscores the shifting landscape of institutional investments in biotech.
Subscribe
Industry News
Stock Market
MGO One Seven LLC Has $451,000 Stock Holdings in Corcept Therapeutics Incorporated $CORT
Photo by Markets Daily
Key Takeaways:
- MGO One Seven LLC trimmed its stake by 8.2%
- 551 shares were sold during the transaction
- The institutional investor now holds 6,142 shares
- The stock holdings are valued at $451,000
- The reduction was disclosed in an SEC filing
MGO One Seven’s Reduced Holdings
MGO One Seven LLC, an institutional investor, decreased its position in Corcept Therapeutics Incorporated in the second quarter. According to the most recent Securities & Exchange Commission filing, the firm cut its holdings by 8.2%. This move indicates a strategic shift in MGO One Seven’s overall biotech investment approach.
Share Count and Valuation
After selling 551 shares of Corcept Therapeutics, MGO One Seven LLC retained 6,142 shares in the biotechnology company. The market value of these shares stands at $451,000. Below is a simple snapshot of the recent change in ownership:
| Transaction | Number of Shares | Approx. Value |
|---|---|---|
| Before Sale | (Not Disclosed) | (Not Disclosed) |
| Sold | 551 | (Not Disclosed) |
| After Sale | 6,142 | $451,000 |
Context of SEC Filing
The details of this transaction came to light through a filing with the SEC, highlighting the importance of transparency and regulatory compliance for institutional investors. Any modification in a significant position—especially within the competitive biotech industry—can offer valuable insights into market trends and investment strategies.
Even after the share reduction, Corcept Therapeutics remains part of MGO One Seven LLC’s portfolio, illustrating the investor’s ongoing confidence in the company’s potential for future growth in the pharmaceutical and biotechnology sector.
